.png){kind=icon}
Siqing Fu
个人简介
暂无内容
教育背景
2001.01 – 2004.12
University of Rochester, Rochester, New York Clinical Fellowship, Section of Hematology and Medical Oncology
1999.01 – 2001.12
University of Rochester, Rochester, New York Residency, Departmental of Internal Medicine
1998.01 – 1999.12
Hospital of Saint Raphael, New Haven, Connecticut Internship, Department of Internal Medicine
1996.01 – 1996.12
The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, US Ph.D Molecular Biology
1996.01 – 1998.12
Yale University School of Medicine, New Haven, Connecticut Postdoctoral Associate, Section of Medical Oncology
1985.01 – 1985.12
Tongji Medical University, Wuhan, US MD
工作经历
2025.01 – 至今
The University of Texas MD Anderson Cancer Center
Committee Member, Medication-Use Safety Team Advisory Committee (MUST)
2014.01 – 至今
The University of Texas MD Anderson Cancer Center
Committee Member, Institutional Review Board (IRB)
2012.01 – 至今
BMC Cancer
Associate Editor
2011.01 – 2018.12
The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Investigational Cancer Therapeutics
2011.01 – 至今
The University of Texas MD Anderson Cancer Center
Member, The Multidisciplinary Research Advisory Committee (MRAC)
2010.01 – 2011.12
The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Assistant Professor
2010.01 – 至今
The University of Texas MD Anderson Cancer Center
member, Credentials Committee of the Medical Staff
2008.01 – 2009.12
S. R. Burzynski Clinic, Houston, TX
Senior Staff Physician
2008.01 – 2008.12
Garfield Medical Center, Monterey Park, CA
Hematology and Oncology Attending
2005.01 – 2007.12
The University of Texas MD Anderson Cancer Center
Member, Faculty Senate
2004.01 – 2008.12
The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Investigational Cancer Therapeutics
2004.01 – 2008.12
The University of Texas MD Anderson Cancer Center
member, Clinical Research Committee
1990.01 – 1996.12
The University of Texas MD Anderson Cancer Center, Houston, Texas
Project Investigator
荣誉奖项
- The 6th Biennial Ovarian Cancer Research Symposium Travel Award（2006）｜Marsha Rivkin Center for Ovarian Cancer Research
- ASCO/AACR Educational Workshop-Methods in Clinical Cancer Research（2002）｜AACR/ASCO
- The Merit Winner at National ACP Meeting at Atlanta, GA（2001）｜American College of Physicians
- The Top Winner at University of Rochester Annual Research Poster Meeting（2000）｜American Physical Society
- The First Place Winner at New York ACP Annual Meeting at Albany, NY（2000）｜American College of Physicians
- American Association for Cancer Research Travel Award（1995）｜American Association for Cancer Research
- The First Place Winner for the Young Scientists（1987）｜Shanghai Association for Pathophysiology
- The First Place Winner for the Young Scientists（1986）｜Chinese Association for Pathophysiology
- The First Place Winner in the English Competition（1983）｜Tongji Medical University
- The Outstanding Student on Research（1982）｜Tongji Medical University
远程医疗作为早期肿瘤学试验的门户：来自14,000名患者的经验教训及全球可及性与公平性的未来方向
贝伐珠单抗和替西罗莫司联合疗法在晚期恶性肿瘤中的I期研究：安全性、有效性和卵巢癌扩展
I期临床试验：奈拉替尼联合帕博西利治疗具有HER家族变异的晚期癌症
自身抗体谱分析以预测罕见肿瘤对PD-1抑制剂帕姆单抗治疗的应答。
髓系靶向抗体PY159和PY314用于铂耐药性卵巢癌
IMPACT 2研究的最终结果，这是一项在MD Anderson癌症中心进行的随机研究，旨在评估转移性癌症中的分子分型和靶向药物。
NC410联合pembrolizumab治疗卵巢癌患者的Ib期研究结果
talazoparib在具有BRCA1/2，DNA修复和PTEN改变的晚期癌症中的II期研究
紫杉烷难治性晚期实体瘤患者TAK-659和紫杉醇的I期研究
avelumab联合utomilumab (4-1BB激动剂)，PF-04518600 (OX40激动剂) 或放疗在晚期妇科恶性肿瘤患者中的1/2期试验
